Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03973372 · ClinicalTrials.gov registry record

ALTA TIPS: A 5-year Longitudinal Observational Study of Patients Undergoing TIPS Placement

A clinical trial of Cirrhosis, Liver and Transjugular Intrahepatic Portosystemic Shunt (TIPS), sponsored by University of Texas Southwestern Medical Center.

Active
Registry status
852
Enrollment target
14
Study locations

NCT03973372: Active study of Cirrhosis, Liver and Transjugular Intrahepatic Portosystemic Shunt (TIPS), sponsored by University of Texas Southwestern Medical Center.

NCT03973372 is a study of Cirrhosis, Liver and Transjugular Intrahepatic Portosystemic Shunt (TIPS) that is active but no longer recruiting, run by University of Texas Southwestern Medical Center. The registered enrollment target is 852 participants, above the 217-participant average among 34 other Cirrhosis, Liver trials with a reported enrollment target (293% higher). The trial reports 14 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03973372, a study of Cirrhosis, Liver and Transjugular Intrahepatic Portosystemic Shunt (TIPS), is active but no longer recruiting, sponsored by University of Texas Southwestern Medical Center.

ACTIVE NOT RECRUITING
Registry status
852 participants
Enrollment target
14
Study locations

Study Summary

ALTA is a multicenter consortium focused on the management of portal hypertension. ALTA TIPS is a longitudinal observational study of patients who are undergoing transjugular intrahepatic portosystemic shunt (TIPS) placement. ALTA will create a database that will provide clinical parameters and outcomes of patients undergoing TIPS as part of their standard of care in hopes of answering key clinical questions.

Primary Outcome

Transjugular Intrahepatic Portosystemic Shunt (TIPS) was first developed as a salvage tool for life threatening variceal bleeding or for the management of severe ascites refractory to medical therapy. Over the past decade there have been improvements in TIPS stent technology resulting in reduction in stent occlusions as well as increased experience of TIPS use. This increase in TIPS use has been paralleled by the expansion of indications for TIPS placement. As TIPS use has increased, so have the

Study Locations (14)

California

  • Stanford - Redwood City
  • Scripps Health - San Diego
  • University of California San Francisco - San Francisco

Illinois

  • Northwestern - Chicago
  • University of Chicago - Chicago

Minnesota

  • University of Minnesota - Minneapolis
  • Mayo Clinic Rochester - Rochester

New York

  • Columbia University - New York
  • Weill Cornell - New York

Texas

  • Baylor Scott & White Liver Consultants of Texas - Dallas
  • University of Texas Southwestern Medical Center - Dallas

Arizona

  • University of Arizona - Phoenix

Florida

  • University of Florida - Gainesville

Wisconsin

  • University of Wisconsin Madison - Madison

Trial Details

FieldValue
Enrollment Target 852 participants
Start Date 2019-06-10
Est. Completion 2027-12

What the registry record for NCT03973372 still lists

NCT03973372 is an observational study that tracks outcomes without assigning an intervention. The registered 852 participants enrollment target is mid-sized for trials with a published cap, above the 217-participant average among 34 other Cirrhosis, Liver trials with a reported enrollment target (293% higher).

The record links to 2 conditions, with Cirrhosis, Liver appearing as the primary indexed condition, and to 0 interventions.

NCT03973372 lists 14 locations in 8 states (California, Illinois, Minnesota).

Frequently Asked Questions

What is clinical trial NCT03973372 about?

NCT03973372 is a clinical study titled "ALTA TIPS: A 5-year Longitudinal Observational Study of Patients Undergoing TIPS Placement". ALTA is a multicenter consortium focused on the management of portal hypertension. ALTA TIPS is a longitudinal observational study of patients who are undergoing transjugular intrahepatic portosystemic shunt (TIPS) placement. ALTA will create a database that will provide clinical parameters and outc...

What is the current status of trial NCT03973372?

This trial is currently active not recruiting. The enrollment target is 852 participants. The study started on 2019-06-10. Estimated completion is 2027-12.

What conditions does trial NCT03973372 study?

This clinical trial studies the following conditions: Cirrhosis, Liver, Transjugular Intrahepatic Portosystemic Shunt (TIPS).

Who is sponsoring clinical trial NCT03973372?

This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03973372 being conducted?

This trial has 14 study locations across Arizona, California, Florida, Illinois, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cirrhosis, Liver

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03973372's enrollment target sits among peer trials

852 3rd of 34 higher than 32 of 34 other Cirrhosis, Liver trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cirrhosis, Liver trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06237452 · 852 participants · Phase 3

    VE303 for Prevention of Recurrent Clostridioides Difficile Infection

  • NCT06422143 · 851 participants · Phase 3

    Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

  • NCT07005102 · 854 participants · Phase 2

    A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

  • NCT07290491 · 854 participants · Phase 3

    Spiritual Care or Psychotherapy Versus Palliative Care Alone in Patients With Non-Curative Malignancies

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03973372, the US trial registry maintained by the National Library of Medicine. NCT03973372 (mid enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.